Deborah A. Jorn
board of director
Orexigen Therapeutics
Orexigen
Australia
Biography
Deborah A. Jorn has served as a member of our board of directors since 2016. Ms. Jorn is a senior commercial strategist with a more than 30-year history of building multi-billion dollar global pharmaceutical businesses and a proven track record of designing and implementing innovative business and marketing strategies that have consistently delivered double-digit organic growth across numerous therapeutic areas. Ms. Jorn is the former Executive Vice President and Group Company Chair at Valeant Pharmaceuticals and was responsible for Valeant’s two largest business units, Dermatology and Gastroenterology, and led a marketing and sales organization encompassing over 100 team members. Prior to Valeant, she was the Chief Global Marketing Officer at Bausch and Lomb Pharmaceuticals and served as the commercial head of their $1.3 billion Global Pharmaceutical Division which included both Rx and OTC brands. She also served in senior commercial leadership roles at Schering Plough, Johnson & Johnson, and Pharmacia. Jorn received a MBA from the Stern Graduate School of Business Administration at New York University and a BA in Biochemistry from Rutgers University.
Research Interest
molecular biology and microbial genetics
